Labiotech.eu

News and Trends 2 Jun 2023

New approach improves cancer treatment and minimizes side effects

Scientists at Tohoku University in Japan have discovered a new approach to improve the efficacy of immune checkpoint blockade (ICB) – a novel form of cancer treatment utilizing immune checkpoint inhibitors (ICIs) – while minimizing the associated side effects. They demonstrated that using ICIs to target tumor-positive lymph nodes generates a robust anti-tumor response against […]

June 2, 2023 - 2 minutesmins - By Jim Cornall

blood bleeding disorders von Willebrand disease

News and Trends 2 Jun 2023

von Willebrand disease treatment gets FDA orphan drug designation

The U.S. Food and Drug Administration (FDA) has granted Vega Therapeutics, Inc. orphan drug designation for its antibody therapy, VGA039, for the treatment of the rare bleeding disorder, von Willebrand disease (VWD). Vega Therapeutics is a clinical stage biotechnology company developing novel therapies for rare blood disorders. VGA039 is a first-in-class antibody therapy with a […]

June 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Jun 2023

Anocca raises $36.6M for large-scale development of cancer cell therapies

Anocca AB has raised SEK 400 million ($36.6 million) to further develop the discovery and manufacture of next generation cell therapies for cancer on an industrial scale. It will also allow Anocca to progress its first products into clinical trials. The financing brings together a group of existing and new investors, including Mellby Gård, AMF, […]

June 2, 2023 - 4 minutesmins - By Jim Cornall

Best in Biotech 1 Jun 2023

Five ophthalmology biotech companies to look out for

There are hundreds of different eye diseases, with some of the most common major eye diseases including age-related macular degeneration (AMD) – an age-related eye disease that can blur central vision – glaucoma – a condition where the optic nerve becomes damaged – and diabetic retinopathy (DR) – a complication of diabetes in which high […]

June 1, 2023 - 6 minutesmins - By Willow Shah-Neville

News and Trends 1 Jun 2023

Swiss researchers develop new class of antibiotics to fight resistant bacteria

Health professionals are in urgent need of new antibiotics to tackle resistant bacteria. Researchers at the University of Zurich (UZH), in Switzerland, and the company Spexis, have now modified the chemical structure of naturally occurring peptides to develop antimicrobial molecules that bind to novel targets in the bacteria’s metabolism. Each year, more than five million […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a phase 2 trial of patients with relapsing multiple sclerosis (MS). Following 12 weeks of therapy, […]

June 1, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

ElevateBio raises $401M for cell and gene therapies

ElevateBio, LLC (ElevateBio), a technology-driven company focused on cell and gene therapies, has closed its $401 million Series D financing. “We have made significant strides in scaling our technologies and end-to-end capabilities in our pursuit to become the world’s most indispensable cell and gene therapy technology company. We are thrilled to welcome Khalil to our […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Fighting obesity with gene therapy

Scientists from the University of Barcelona in Spain and the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) have designed a strategy to fight obesity and diabetes in mice through ex vivo gene therapy. The technique consists of implanting cells that have been manipulated and transformed in order to treat a disease. This […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Lonza boosts ADC portfolio with Synaffix acquisition

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs). While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which […]

June 1, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy

CRISPR-based microbial gene therapy company SNIPR Biome ApS has announced positive interim clinical results from its phase 1 clinical trial with SNIPR001. SNIPR Biome’s SNIPR001 is the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract. The work was supported by CARB-X, a global […]

June 1, 2023 - 3 minutesmins - By Jim Cornall

In Depth 31 May 2023

Biotechnology in developing countries: challenges and opportunities

Choosing to grow their biotechnology sectors can offer developing countries vast opportunities, helping them to grow economically, providing new jobs, and supporting sustainable development, public health, and environmental protection. In recent times, significant growth has been achieved by the developing world in biotechnology fields, mainly tied to food production, healthcare, and other dimensions of human […]

May 31, 2023 - 7 minutesmins - By Willow Shah-Neville

News and Trends 31 May 2023

Artificial intelligence combats lethal superbug, new antibiotic discovered

A new antibiotic called abaucin that can kill a deadly, drug-resistant pathogen has been discovered with the help of artificial intelligence (AI). Research published in Nature Chemical Biology showed that AI was able to rapidly screen 7,500 molecules that were found to inhibit the growth of the superbug Acinetobacter baumannii, a task that would be […]

May 31, 2023 - 3 minutesmins - By Roohi Mariam Peter

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

New approach improves cancer treatment and minimizes side effects

von Willebrand disease treatment gets FDA orphan drug designation

Anocca raises $36.6M for large-scale development of cancer cell therapies

Five ophthalmology biotech companies to look out for

Swiss researchers develop new class of antibiotics to fight resistant bacteria

Sanofi drug reduces disease activity in relapsing MS

ElevateBio raises $401M for cell and gene therapies

Fighting obesity with gene therapy

Lonza boosts ADC portfolio with Synaffix acquisition

SNIPR Biome sees positive results for first-in-human CRISPR microbial gene therapy

Biotechnology in developing countries: challenges and opportunities

Artificial intelligence combats lethal superbug, new antibiotic discovered

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!